Clinical Trial Update: Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on post-transplant cyclophosphamide for graft-versus-host disease prophylaxis completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allogeneic Transplant
• Aplastic Anemia
• Leukemia
• Lymphoma
• Myelodysplastic Syndrome
• Myelofibrosis

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Leukemia, Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2022-06-15